论文部分内容阅读
目的探讨阿托伐他汀钙对维持性肾透析患者血清超敏C反应蛋白(hs-CRP)、白细胞介素-1β(IL-1β)、白介素-6(IL-6)水平的影响。方法选取慢性肾功能衰竭(尿毒症期)且开始进行长期维持性血液透析治疗患者140例,随机分为观察组与对照组各70例。2组患者均给予维持性血液透析治疗,观察组患者给予阿托伐他汀钙20mg口服,每天1次。对照组患者给予阿托伐汀钙10mg口服,每天1次。治疗观察时间为6个月。分别于治疗前后抽取静脉血检测血清hs-CRP、IL-β及IL-6水平的变化。结果 2组患者治疗后血清hs-CRP、IL-6、IL-1β水平与治疗前比较明显减少,且观察组血清hs-CRP、IL-6、IL-1β水平明显低于对照组,差异均有统计学意义(P<0.05)。结论阿托伐他汀钙长期服用有助于减轻维持性血液透析患者体内的微炎性反应,其中每次20mg剂量阿托伐他汀钙临床应用效果优于每次10mg剂量。
Objective To investigate the effects of atorvastatin calcium on serum hs-CRP, IL-1β and IL-6 in maintenance renal dialysis patients. Methods A total of 140 patients with chronic renal failure (uremia) who started long-term maintenance hemodialysis were randomly divided into observation group (70 cases) and control group (70 cases). Patients in both groups were given maintenance hemodialysis. Patients in the observation group were given 20 mg of atorvastatin calcium orally once daily. Patients in the control group were given 10 mg of atorvastatin calcium orally once daily. The treatment observation time was 6 months. The changes of serum hs-CRP, IL-β and IL-6 levels in venous blood before and after the treatment were detected. Results The serum levels of hs-CRP, IL-6 and IL-1β in the two groups were significantly decreased after treatment, and the levels of hs-CRP, IL-6 and IL-1β in the observation group were significantly lower than those in the control group There was statistical significance (P <0.05). Conclusions Long-term administration of atorvastatin will help to reduce the micro-inflammatory response in maintenance hemodialysis patients. The effect of 20 mg atorvastatin is better than 10 mg at each time.